These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32446629)

  • 1. Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma.
    Noda T; Komune N; Yasumatsu R; Tsuchihashi NA; Tamae A; Matsumoto N; Sato K; Uchi R; Koike K; Wakasaki T; Tanaka R; Nakagawa T
    Auris Nasus Larynx; 2020 Oct; 47(5):864-869. PubMed ID: 32446629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
    Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck.
    Suzuki S; Toyoma S; Tomizawa H; Yamada T; Iikawa N; Shiina K; Saito H; Koizumi K; Kawasaki Y; Yamada T
    Auris Nasus Larynx; 2020 Jun; 47(3):485-488. PubMed ID: 31248647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
    Ueda Y; Okano S; Enokida T; Fujisawa T; Ito K; Sato M; Tanaka H; Wada A; Tahara M
    Oral Oncol; 2022 Jul; 130():105932. PubMed ID: 35636078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab.
    Ueda T; Chikuie N; Takumida M; Furuie H; Kono T; Taruya T; Hamamoto T; Hattori M; Ishino T; Takeno S
    Acta Otolaryngol; 2020 Feb; 140(2):181-187. PubMed ID: 31825711
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
    Knochelmann HM; Horton JD; Liu S; Armeson K; Kaczmar JM; Wyatt MM; Richardson MS; Lomeli SH; Xiong Y; Graboyes EM; Lentsch EJ; Hornig JD; Skoner J; Stalcup S; Spampinato MV; Garrett-Mayer E; O'Quinn EC; Timmers CD; Romeo MJ; Wrangle JM; Young MRI; Rubinstein MP; Day TA; Lo RS; Paulos CM; Neskey DM
    Cell Rep Med; 2021 Oct; 2(10):100426. PubMed ID: 34755137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
    Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
    Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab.
    Tachinami H; Tomihara K; Yamada SI; Ikeda A; Imaue S; Hirai H; Nakai H; Sonoda T; Kurohara K; Yoshioka Y; Hasegawa T; Naruse T; Niiyama T; Shimane T; Ueda M; Yanamoto S; Akashi M; Umeda M; Kurita H; Miyazaki A; Arai N; Hayashi R; Noguchi M
    Br J Oral Maxillofac Surg; 2023 May; 61(4):320-326. PubMed ID: 37061418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the prognostic role of pSTAT3 expression in temporal bone squamous cell carcinoma.
    Marioni G; Nucci R; Marino F; Cappellesso R; Pillon M; Zanoletti E; Giacomelli L; Franchella S; Billo P; Pareschi R; Martini A
    Otol Neurotol; 2013 Oct; 34(8):1476-82. PubMed ID: 24005169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
    N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study.
    Okamoto I; Sato H; Kondo T; Koyama N; Fushimi C; Okada T; Miura K; Matsuki T; Yamashita T; Omura G; Tsukahara K
    Acta Otolaryngol; 2019 Oct; 139(10):918-925. PubMed ID: 31460818
    [No Abstract]   [Full Text] [Related]  

  • 16. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report.
    Takemoto K; Miyahara N; Chikuie N; Hamamoto T; Ishino T; Ueda T; Takeno S
    Auris Nasus Larynx; 2019 Oct; 46(5):813-817. PubMed ID: 30442438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab in patients with rare head and neck carcinomas: A single center's experience.
    Kokkali S; Ntokou A; Drizou M; Perdikari K; Makaronis P; Katsarou E; Koufopoulos N; Tzovaras A; Ardavanis A
    Oral Oncol; 2020 Feb; 101():104359. PubMed ID: 31300270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer.
    Yasumatsu R; Wakasaki T; Hashimoto K; Nakashima K; Manako T; Taura M; Matsuo M; Nakagawa T
    Head Neck; 2019 Aug; 41(8):2610-2618. PubMed ID: 30835919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.